Pfizer receives warning letter over EpiPen manufacturing; Opdivo kidney-cancer trial shows improved survival rates; cancer patients who discuss costs with physicians pay less
Merck CEO leaves Trump’s manufacturing council over Charlottesville response; researchers struggle to fill clinical trials for IO drugs; Roche shareholders sue over top-line results
Five things for pharma marketers to know: Friday, July 28, 2017
Drugmakers inconsistently share clinical trial data; AstraZeneca’s share price falls after Mystic results; some pregnancy apps share info with marketers
Five things for pharma marketers to know: Tuesday, June 27, 2017
Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors